Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and
preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced
or metastatic solid tumors harboring RET mutations or alterations. The study consists of
three portions: 1) Phase 1 Dose Escalation and Food Effect Sub-study, and 2) Phase 1 dose
expansion and 3) Phase 2 efficacy evaluation.